Financial Information for the 1st Quarter of Fiscal Year Ending March 31, 2021

As of August 4, 2020

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

(Note about forward-looking information)
The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1 Summary of Financial Results for the 1st Quarter of FY2020 Ending March 31, 2021 and Forecasts for FY2020

1. Summary of Financial Results for the 1st Quarter of FY2020 … … 2
2. Summary of Forecasts for FY2020

2 Consolidated Financial Indicators for the 1st Quarter of FY2020

1. Profit and Loss … … 3
(1) Profit and Loss … … 3
(2) Sales Revenue of Main Products … … 3
2. Financial Statement … … 4
(1) Balance Sheet … … 4
(2) Cash Flow Statement … … 4
(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems … … 4
(4) Depreciation and Amortization Costs

3 Forecasts for FY2020

(1) Consolidated Forecasts of Profit and Loss … … 5
(2) Sales Revenue Forecasts for Main Products … … 5

4 Five-Year Financial Data

(1) Profit and Loss (2) Balance Sheet (3) Other Financial Data (4) Number of Employees … … 6

5 Quarterly Trend

(1) Profit and Loss … … 7
(2) Sales Revenue of Main Products … … 8

6 State of New Product Development (As of July 25, 2020)

(1) Immune-inflammation (2) Diabetes and kidney … … 9
(3) Central nervous system (4) Vaccines … … 10
(5) Others … … 11
Changes Since Previous Announcement … … 11

1 Summary of Financial Results for the 1st Quarter of FY2020 Ending March 31, 2021 and Forecasts for FY2020

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2020, the forecast is prepared on the assumption that the arbitration procedure to continue.
MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for the 1st Quarter of FY2020

(Amounts less than ¥100 million are rounded off)

[Billion yen]

Revenue	91.8	Y-on-Y	(6.3)	(6.5 %)
Domestic	75.7	Y-on-Y	(5.0)	(6.2 %)
Overseas	16.1	Y-on-Y	(1.3)	(7.5 %)

Domestic ethical drugs sales decreased by 6.2% to ¥73.3 billion year-on-year, due to NHI price revision and expansion of generic drugs, despite increase of some priority products, SIMPONI for Rheumatoid arthritis (RA) treatment, CANAGLU and CANALIA for type 2 diabetes mellitus treatment and RUPAFIN for allergy treatment , as well as STELARA which was additionally approved for the treatment for ulcerative colitis in March 2020.
Royalty revenue, etc. decreased by 25.7% to ¥3.8 billion year-on-year due mainly to the decline in royalty revenue from GILENYA for multiple sclerosis treatment licensed to Novartis.

[Billion yen]

Core Operating Profit*	9.6	Y-on-Y	(0.2)	(1.8 %)

Core operating profit almost unchanged due to SG&A and R&D expenses contained by voluntary restraint in activities under COVID-19 spread, despite decrease in domestic ethical drugs sales and royalty revenue.

*With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

[Billion yen]

Operating Profit	17.7	Y-on-Y	8.0	83.6 %

¥8.1 billion of gain from fixed assets in transfer of Toda office, etc. recognized as non recurring items.

[Billion yen]

Profit before tax for the period	17.8	Y-on-Y	8.6	93.7 %
Net Income Attributable to owners of the Company	11.5	Y-on-Y	4.6	67.1 %

2. Summary of Forecasts for FY2020

[Billion yen]

Revenues	383.5	Y-on-Y	3.7	1.0 %
Core Operating Profit	10.0	Y-on-Y	(9.1)	(47.5 %)
Operating Profit	17.0	Y-on-Y	23.1	-
Profit before Tax	17.5	Y-on-Y	24.0	-
Net Income Attributable to owners of the Company	8.5	Y-on-Y	8.4	-

Forecasts remain unchanged from those announced on May 13, 2020, which exclude the impact of novel coronavirus (COVID-19) infection.

2 Consolidated Financial Indicators for the 1st Quarter of FY2020

(Amounts less than ¥100 million are rounded up)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	Q1 FY2020	Comparison to previous year			Comparison to Forecasts		Notes [Y-on-Y comparison]
		Q1 FY2019	Increase (decrease)	Change %	Forecasts*1	Change %	
Revenue	**91.8**	98.1	(6.3)	(6.5)	383.5	23.9	Refer to "(2) Sales Revenue of Main Products"
Domestic	**75.7**	80.8	(5.0)	(6.2)	314.1	24.1	
Overseas	**16.1**	17.4	(1.3)	(7.5)	69.4	23.1	
Overseas sales ratio	**17.5%**	17.7%			18.1%		
Cost of sales	**45.6**	44.8	0.8	1.8	187.5	24.3	Deteriorated by NHI price revision,etc.
Sales cost ratio	**49.7%**	45.6%			48.9%		
Gross profit	**46.2**	53.3	(7.2)	(13.4)	196.0	23.6	
SG&A expenses,etc.	**36.6**	43.6	(7.0)	(16.0)	186.0	19.7	
R&D expenses	**15.3**	19.9	(4.6)	(23.3)	83.5	18.3	
Core operating profit	**9.6**	9.8	(0.2)	(1.8)	10.0	95.8	
Non-recurring items*2	**8.1**	(0.1)	8.2	-	7.0	115.6	Gain from sales of Toda Office, etc.
Operating profit	**17.7**	9.6	8.0	83.6	17.0	103.9	
Financial income and loss*2	**0.2**	(0.4)	0.6	-			
Profit before tax for the period	**17.8**	9.2	8.6	93.7	17.5	101.9	
Income taxes	**6.9**	3.6	3.3	93.1			
Net profit for the period	**10.9**	5.6	5.3	94.1	5.5	198.0	
Net profit attributable to owners of the Company	**11.5**	6.9	4.6	67.1	8.5	135.3	

[Yen]

Exchange rate	Q1 FY2020 average	Q1 FY2019 average	FY2020 planned
USD	**107.38**	109.67	108.00

Effect of fluctuations in exchange rate for FY2020 Q1: Revenue decreased by ¥0.4 bil. and core operating profit increased by ¥0.4 bil.

(2) Sales Revenue of Main Products

[Billion yen]

	Q1 FY2020	Comparison to previous year			Comparison to Forecasts	
		Q1 FY2019	Increase (decrease)	Change %	Forecasts*1	Change %
Domestic ethical drugs	**73.3**	78.2	(4.9)	(6.2)	303.6	24.1
Priority products	**45.3**	46.5	(1.2)	(2.5)	182.3	24.9
Remicade	**11.9**	14.4	(2.6)	(17.7)	44.8	26.6
Simponi	**10.7**	10.5	0.2	1.4	42.3	25.2
Stelara	**7.0**	6.2	0.8	12.5	32.8	21.2
Tenelia	**4.1**	4.7	(0.6)	(12.7)	14.9	27.5
Canaglu	**2.5**	2.2	0.4	17.3	9.2	27.7
Canalia	**2.5**	2.2	0.3	15.3	9.3	27.2
Lexapro	**3.9**	3.9	(0.0)	(0.6)	14.6	26.5
Rupafin	**1.7**	1.3	0.4	33.1	10.2	16.2
Imusera	**1.1**	1.1	(0.0)	(4.2)	4.1	26.5
Vaccines	**7.5**	7.3	0.2	3.0	41.0	18.3
Influenza vaccine	**(0.0)**	(0.0)	(0.0)	-	12.2	(0.3)
Tetrabik	**2.7**	2.4	0.3	12.9	11.3	23.8
Mearubik	**1.9**	1.9	(0.0)	(0.4)	6.4	29.4
JEBIK V	**1.4**	1.5	(0.1)	(4.1)	5.3	27.1
Varicella vaccine	**1.3**	1.3	(0.0)	(2.1)	4.8	26.1
Long-listed drugs, etc.	**20.4**	24.3	(3.9)	(16.1)	80.3	25.4
Overseas ethical drugs	**12.6**	12.6	0.0	0.4	50.9	24.8
Radicava	**5.6**	6.1	(0.5)	(8.9)	22.4	24.9
Royalty revenue, etc.	**3.8**	5.1	(1.3)	(25.7)	19.9	18.9
Royalty from INVOKANA	**2.0**	2.1	(0.0)	(0.4)	Undisclosed	–
Royalty from GILENYA*3	**1.1**	1.7	(0.6)	(36.9)	Undisclosed	–

*1: The Company announced full-year forecasts on May 13, 2020.

*2: Brackets indicate expense and loss

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of Q1 FY2020	End of FY2019	Increase (decrease)	Notes
Assets	**1,058.9**	1,046.3	12.6	
Non-current assets	**457.7**	452.8	4.8	
Property, plant and equipment	**88.9**	86.1	2.8	Obtain:5.6, depreciation:(2.8)
Goodwill	**89.7**	89.7	0.0	
Intangible assets	**181.0**	181.3	(0.3)	
Other non-current assets	**98.0**	95.7	2.3	
Current assets	**601.2**	593.5	7.8	
Inventories	**86.4**	80.3	6.0	
Trade and other receivables	**112.5**	108.6	3.9	
Other financial assets	**288.7**	300.3	(11.5)	
Cash and cash equivalents	**100.7**	83.1	17.7	Refer to "(2) Cash Flow Statement"
Other current assets	**13.0**	21.2	(8.3)	assets held for sales(5.8)
Liabilities	**188.0**	188.4	(0.4)	
Non-current liabilities	**99.0**	90.3	8.6	
Other non-current liabilities	**49.3**	40.9	8.4	
Other	**49.6**	49.4	0.2	
Current liabilities	**89.0**	98.0	(9.0)	
Trade and other payables	**35.3**	32.1	3.2	
Other	**53.7**	65.9	(12.2)	
Equity	**870.9**	857.9	13.0	
Share capital	**50.0**	50.0	-	
Capital surplus	**448.0**	448.0	(0.1)	
Retained earnings	**372.7**	358.4	14.3	Net profit for the period 11.5
Other components of equity	**0.3**	1.5	(1.2)	

(2) Cash Flow Statement

[Billion yen]

	Q1 FY2020	Q1 FY2019	Increase (decrease)
Cash and cash equivalents at beginning of year	**83.1**	111.9	(28.8)
Cash flows from operating activities	**0.9**	5.2	(4.3)
Profit before tax	**17.8**	9.2	8.6
Depreciation and amortization	**3.7**	3.8	(0.0)
Loss on sales of Property, Plant and Equipment	**(8.1)**	-	(8.1)
Trade receivable and payable	**(0.7)**	(0.7)	0.0
Other	**(11.9)**	(7.0)	(4.8)
Cash flows from investing activities	**17.5**	6.8	10.7
Purchase (proceeds from sales) of property, plant and equipment	**8.1**	(3.4)	11.4
Purchase (Proceeds from sales) of investments	**64.7**	10.1	54.5
Increase in deposits	**(60.0)**	(0.2)	(59.9)
Other	**4.8**	0.1	4.6
Cash flows from financing activities	**(0.7)**	(17.7)	17.0
Effect of exchange rate changes on cash and cash equivalents	**(0.0)**	(0.9)	0.9
Net increase(decrease) in cash and cash equivalents	**17.7**	(6.6)	24.2
Increase by transfer to assets held for sales	**-**	0.1	(0.1)
Cash and cash equivalents at the end of period	**100.7**	105.4	(4.7)

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

occurring basis	Q1 FY2020	Q1 FY2019	Increase (decrease)
Investment in property, plant and equipment	**5.6**	2.9	2.7
Investment in information systems	**0.3**	0.2	0.1

(4) Depreciation and Amortization Costs

[Billion yen]

	Q1 FY2020	Q1 FY2019	Increase (decrease)
Property, plant and equipment	**2.8**	2.8	0.0
Intangible assets	**0.3**	0.3	(0.0)
Intangible assets with products	**0.6**	0.6	(0.0)

3 Forecasts for FY2020

(Amounts less than ¥ 100 million are rounded up)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	FY2020 forecasts*1	Comparison to previous year			Notes [Y-on-Y Comparison]
		FY2019 actual	Increase (decrease)	Change %	
Revenue	**383.5**	379.8	3.7	1.0	Refer to "(2) Sales Revenue Forecasts for Main Products"
Domestic	**314.1**	314.0	0.1	0.0	
Overseas	**69.4**	65.8	3.6	5.4	
Overseas sales ratio	**18.1%**	17.3%			
Cost of sales	**187.5**	181.0	6.5	3.6	Increase due to the influence of NHI price revision, etc.
Sales cost ratio	**48.9%**	47.7%			
Gross profit	**196.0**	198.8	(2.8)	(1.4)	
SG&A expenses, etc.	**186.0**	179.7	6.3	3.5	Promote reforming operational productivity and reduce expenses. On the other hand, expect an increase in expenses for preparation for sales of global projects
R&D expenses	**83.5**	79.4	4.1	5.1	Increase due to clinical study expenses primarily for global projects
Core operating profit	**10.0**	19.1	(9.1)	(47.5)	
Non-recurring items*2	**7.0**	(25.1)	32.1	-	
Operating profit*2	**17.0**	(6.1)	23.1	-	
Profit before tax for the period*2	**17.5**	(6.5)	24.0	-	
Net profit for the period*2	**5.5**	(9.4)	14.9	-	
Net profit attributable to owners of the Company	**8.5**	0.1	8.4	-	

Exchange rate

[Yen]

	FY2020 planned	FY2019 average
USD	**108.00**	108.95

(2) Sales Revenue Forecasts for Main Products

[Billion yen]

	FY2020 forecasts*1	Comparison to previous year		
		FY2019 actual	Increase (decrease)	Change %
Domestic ethical drugs	**303.6**	304.4	(0.8)	(0.3)
Priority products	**182.3**	177.1	5.2	2.9
Remicade	**44.8**	53.4	(8.6)	(16.1)
Simponi	**42.3**	41.0	1.3	3.2
Stelara	**32.8**	26.0	6.8	26.2
Tenelia	**14.9**	15.2	(0.3)	(1.9)
Canaglu	**9.2**	8.8	0.3	3.4
Canalia	**9.3**	6.7	2.6	38.4
Lexapro	**14.6**	15.0	(0.3)	(2.1)
Rupafin	**10.2**	6.8	3.5	51.3
Imusera	**4.1**	4.2	(0.1)	(2.3)
Vaccines	**41.0**	39.0	2.0	5.1
Influenza vaccine	**12.2**	12.6	(0.4)	(3.1)
Tetrabik	**11.3**	9.5	1.8	18.7
Mearubik	**6.4**	6.0	0.5	8.3
JEBIK V	**5.3**	5.2	0.2	3.4
Varicella vaccine	**4.8**	4.9	(0.1)	(1.7)
Long-listed drugs, etc.	**80.3**	88.3	(8.0)	(9.1)
Overseas ethical drugs	**50.9**	49.7	1.2	2.4
Radicava	**22.4**	23.1	(0.8)	(3.3)
Royalty revenue, etc.	**19.9**	17.4	2.5	14.1
Royalty from INVOKANA	**Undisclosed**	8.5	-	-
Royalty from GILENYA*3	**Undisclosed**	5.7	-	-

*1: No change from the forecasts announced on May 13, which exclude the impact of COVID-19 infection.

*2: Brackets indicate expense and loss

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded up)

(1) Profit and Loss

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	Q1 FY2020	FY2020 forecasts
Revenues	424.0	433.9	424.8	379.8	91.8	383.5
Cost of sales	164.4	169.8	180.6	181.0	45.6	187.5
Gross profit	259.6	264.1	244.1	198.8	46.2	196.0
SG&A expenses, etc.	165.1	185.6	188.3	179.7	36.6	186.0
R&D expenses	64.8	79.1	86.5	79.4	15.3	83.5
Core operating profit	94.5	78.5	55.8	19.1	9.6	10.0
Operating profit	94.1	77.3	50.3	(6.1)	17.7	17.0
Profit before tax	96.1	78.8	50.4	(6.5)	17.8	17.5
Net profit for the period	68.9	54.0	32.2	(9.4)	10.9	5.5
Net profit attributable to owners of the Company	71.3	58.0	37.4	0.1	11.5	8.5

(2) Balance Sheet

[Billion yen]

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of Q1 FY2020
Assets	984.5	1,048.4	1,056.3	1,046.3	1,058.9
Non-current assets	300.8	462.9	467.9	452.8	457.7
Current assets	683.8	585.5	588.4	593.5	601.2
Liabilities	113.1	153.6	146.0	188.4	188.0
Non-current liabilities	24.7	55.4	54.3	90.3	99.0
Current liabilities	88.4	98.2	91.7	98.0	89.0
Equity	871.4	894.8	910.3	857.9	870.9

(3) Other Financial Data

[Billion yen]

	FY2016	FY2017	FY2018	FY2019	Q1 FY2020	FY2020 forecasts
Cash flows from operating activities	59.8	66.9	41.5	49.4	0.9	-
Cash flows from investing activities	(10.6)	(19.2)	(31.2)	(39.2)	17.5	-
Cash flows from financing activities	(24.4)	(32.5)	(25.9)	(37.9)	(0.7)	-
Investments in property, plant and equipment	14.5	6.2	8.6	15.5	5.9	18.2
Depreciation and Amortization Costs	10.5	11.5	11.5	10.9	3.7	15.7
Property, plant and equipment	7.3	7.6	7.1	7.0	2.8	11.4
Intangible assets including intangible assets with products	3.1	4.0	4.4	4.0	0.9	4.3
Ratio of equity attributable to owners of the Company to total assets [%]	87.4	84.2	85.0	81.4	81.8	-
ROE [%]	8.5	6.6	4.2	0.0	-	-
Basic earnings per share [¥]	127.03	103.35	66.64	0.26	-	-
Equity attributable to owners of the Company per share [¥]	1,533.91	1,574.26	1,600.64	1,519.22	1,543.26	-

(4) Number of Employees

	End of FY2016	End of FY2017	End of FY2018	End of FY2019	End of Q1 FY2020	Forecasts for end of FY2020
Consolidated	7,280	7,187	7,228	6,987	6,985	7,000
Non-consolidated	4,239	4,222	4,111	3,764	3,564	3,450

5 Quarterly Trend

(Amounts less than ¥ 100 million are rounded up)

(1) Profit and Loss

[Billion yen]

	FY2019					FY2020	
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year Actual	Q1 Apr. to Jun.	Full-year Forecasts
Revenue	98.1	90.0	109.3	82.4	379.8	91.8	383.5
	25.8%	23.7%	28.8%	21.7%	100.0%	23.9%	100.0%
Domestic	80.8	73.9	92.6	66.7	314.0	75.7	314.1
	25.7%	23.5%	29.5%	21.3%	100.0%	24.1%	100.0%
Overseas	17.4	16.1	16.7	15.7	65.8	16.1	69.4
	26.4%	24.5%	25.3%	23.8%	100.0%	23.1%	100.0%
Cost of sales	44.8	43.7	54.6	38.0	181.0	45.6	187.5
Sales cost ratio	45.6%	48.6%	49.9%	46.1%	47.7%	49.7%	48.9%
Gross profit	53.3	46.3	54.7	44.5	198.8	46.2	196.0
	26.8%	23.3%	27.5%	22.4%	100.0%	23.6%	100.0%
SG&A expenses, etc.	43.6	44.3	42.3	49.6	179.7	36.6	186.0
	24.3%	24.7%	23.5%	27.6%	100.0%	19.7%	100.0%
R&D expenses	19.9	19.9	17.8	21.9	79.4	15.3	83.5
	25.1%	25.0%	22.4%	27.6%	100.0%	18.3%	100.0%
Core operating profit*	9.8	1.9	12.5	(5.1)	19.1	9.6	10.0
	51.2%	10.2%	65.5%	(26.9%)	100.0%	95.8%	100.0%
Operating profit*	9.6	2.9	12.4	(31.1)	(6.1)	17.7	17.0
	-	-	-	-	-	103.9%	100.0%
Profit before tax*	9.2	2.9	12.5	(31.1)	(6.5)	17.8	17.5
	-	-	-	-	-	101.9%	100.0%
Net profit attributable to owners of the Company*	6.9	1.4	9.9	(18.1)	0.1	11.5	8.5
	-	-	-	-	-	135.3%	100.0%

Note: The progress rates show in the lower of each cell, except for "cost of sales".

*Brackets indicate expense and loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2019					FY2020	
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Full-year Forecasts
Domestic ethical drugs	78.2	71.0	90.5	64.7	304.4	73.3	303.6
	25.7%	23.3%	29.7%	21.3%	100.0%	24.1%	100.0%
Priority products	46.5	42.2	49.1	39.2	177.1	45.3	182.3
	26.3%	23.8%	27.7%	22.2%	100.0%	24.9%	100.0%
Remicade	14.4	13.2	14.9	10.9	53.4	11.9	44.8
	27.1%	24.7%	27.9%	20.4%	100.0%	26.6%	100.0%
Simponi	10.5	9.9	11.2	9.3	41.0	10.7	42.3
	25.7%	24.3%	27.5%	22.6%	100.0%	25.2%	100.0%
Stelara	6.2	6.4	7.8	5.7	26.0	7.0	32.8
	23.8%	24.6%	29.9%	21.8%	100.0%	21.2%	100.0%
Tenelia	4.7	3.4	4.0	3.1	15.2	4.1	14.9
	30.9%	22.3%	26.3%	20.5%	100.0%	27.5%	100.0%
Canaglu	2.2	1.9	2.5	2.3	8.8	2.5	9.2
	24.4%	22.0%	28.1%	25.5%	100.0%	27.7%	100.0%
Canalia	2.2	1.6	1.8	1.2	6.7	2.5	9.3
	32.7%	23.0%	26.1%	18.2%	100.0%	27.2%	100.0%
Lexapro	3.9	3.6	4.2	3.3	15.0	3.9	14.6
	26.1%	23.8%	27.9%	22.3%	100.0%	26.5%	100.0%
Rupafin	1.3	1.2	1.7	2.6	6.8	1.7	10.2
	18.5%	18.4%	24.6%	38.5%	100.0%	16.2%	100.0%
Imusera	1.1	1.0	1.2	0.9	4.2	1.1	4.1
	27.0%	24.4%	27.7%	20.9%	100.0%	26.5%	100.0%
Vaccines	7.3	8.4	17.2	6.1	39.0	7.5	41.0
	18.7%	21.6%	44.1%	15.6%	100.0%	18.3%	100.0%
Influenza vaccine	(0.0)	1.8	10.6	0.2	12.6	(0.0)	12.2
	(0.1%)	14.3%	84.3%	1.6%	100.0%	(0.3%)	100.0%
Tetrabik	2.4	2.2	2.5	2.4	9.5	2.7	11.3
	25.0%	23.2%	26.5%	25.3%	100.0%	23.8%	100.0%
Mearubik	1.9	1.6	1.3	1.2	6.0	1.9	6.4
	31.9%	27.1%	21.2%	19.8%	100.0%	29.4%	100.0%
JEBIK V	1.5	1.4	1.3	1.0	5.2	1.4	5.3
	29.3%	26.6%	25.1%	19.0%	100.0%	27.1%	100.0%
Varicella vaccine	1.3	1.2	1.3	1.1	4.9	1.3	4.8
	26.2%	24.7%	26.1%	23.1%	100.0%	26.1%	100.0%
Long-listed drugs, etc.	24.3	20.4	24.2	19.4	88.3	20.4	80.3
	27.6%	23.1%	27.4%	22.0%	100.0%	25.4%	100.0%
Overseas ethical drugs	12.6	12.3	12.6	12.2	49.7	12.6	50.9
	25.3%	24.7%	25.4%	24.6%	100.0%	24.8%	100.0%
Radicava	6.1	5.5	5.7	5.8	23.1	5.6	22.4
	26.5%	23.8%	24.8%	24.9%	100.0%	24.9%	100.0%
Royalty revenue, etc.	5.1	4.2	4.4	3.8	17.4	3.8	19.9
	29.0%	23.9%	25.2%	21.9%	100.0%	18.9%	100.0%
Royalty from INVOKANA	2.1	2.0	2.4	2.0	8.5	2.0	Undisclosed
	24.2%	23.9%	28.3%	23.7%	100.0%	-	-
Royalty from GILENYA*1	1.7	1.6	1.4	1.1	5.7	1.1	Undisclosed
	29.3%	27.7%	23.8%	19.2%	100.0%	-	-

Note: The each figure in the lower displays the progress rate.

*1: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

6 State of New Product Development (as of July 25, 2020)

i. Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
MT-1303 (Amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe Phase 2	In-house
	(Crohn's disease)	Japan Phase 2	
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house
	(Seasonal Allergic Rhinitis)	Phase 1	

ii. Diabetes and kidney

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
	(Diabetic nephropathy)	Asia Filed	
		Japan Phase 3	
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Filed (Sep. 2019)	
		Europe Phase 2	
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	In-house
		Japan Phase 2	
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2	

※ Asia: excluding Japan and China

iii. Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Japan Filed (June 2020) Asia Phase 3	Licensed from Viela Bio (US)
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Phase 2/3 Asia Filed	Licensed from Neurocrine Biosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMa antibody (Spinal cord injury)	Phase 1	Co-developed with Osaka University (Japan)

iv. Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019) Europe Phase 3	Medicago product (Canada)
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3	
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Phase 1	Medicago product (Canada)

※ Asia: excluding Japan and China

v. Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/licensee
TAU-284 Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Allergic rhinitis, Urticaria)	Asia Filed	Licensed from Ube Industries (Japan)
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-4129	Cardiovascular system, etc.	Phase 1	In-house
MT-8633/TR1801-ADC	Anti-c-Met ADC* (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

*Antibody drug conjugate

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of July 25, 2020	Origin / licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	Thailand Approved (Apr. 2020)	In-house
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Europe Filed (July 2019)	Europe Approved (June 2020)	Licensed to Janssen Pharmaceuticals (US)
		None	Asia Filed	In-house
MT-6548 (Vadadustat)	Hypoxia inducible factor prolyl hydroxylase inhibitor (Renal anemia)	Japan Filed (July 2019)	Japan Approved (June 2020)	Licensed from Akebia (US)
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	Indonesia Approved (July 2020)	In-house
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Japan, Asia Phase 3	Japan Filed (June 2020)	Licensed from Viela Bio (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 2	Global Phase 3	In-house
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	None	Phase 1	Medicago product (Canada)
ND0701 (Apomorphine)	Continuous SC pump (Parkinson's disease)	Phase 1	Deleted (Discontinued)	In-house
MT-6345	Nervous system	Phase 1	Deleted (Discontinued)	Co-developed with Ube Industries (Japan)

※ Asia: excluding Japan and China